Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.CONCLUSIONSThese data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, DNL has been associated with hepatic and whole-body IR (glucose metabolism),24,25 suggesting that IR may accelerate hepatic DNL.25”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [25]
In the citing paper
“In a well-designed study by Smith et al. [50], the contribution of hepatic DNL to intrahepatic TG palmitate was 11%, 19%, and 38% in the lean, obese, and obese-MASLD groups, respectively.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
In the citing paper
“Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“First, the long (3-5 week) duration of D2O tracer administration in our study accounted for labelling of the liver TG pools that turn over slowly (12) and provided an integrated assessment of DNL during daily fasting and fed conditions over several weeks.”
BackgroundMethodResultInfluentialA new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 2×
“The initial daily energy content of the diet provided 75% of estimated energy requirements (54); subsequent meals and energy”
BackgroundMethodObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Self-citationNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Although the mechanism(s) responsible for the increase in hepatic DNL in people with NAFLD is not known, it is possible that increases in circulating insulin and glucose associated with hepatic and whole-body insulin resistance are involved in stimulating hepatic DNL because insulin and glucose activate SREBP-1c and C…”
Background
Research works printed but not linked: 2
- 10.1172/JCI22422 · DOI · Paper page
- 10.1016/S1097-2765(05)00010-9 · doi:10.1016/s1097-2765(05)00010-9 · Paper page
Cited by
Items 701–770 of 770
Rôle des sphingolipides hépatiques dans la physiopathologie du diabète de type 2
Lachkar, F. (2022) · theses.fr (ABES) · doi:10.70675/2f1ce169zade5z47ccz96caz55bf77edab09
Tesoro, N. A., Rivera, F. B., Bantayan, N. R. B., Magalong, J. V., Tomada, R., Wong, M. A., Tangco, G. A., Pine, P. L. S., Manha, J. K., Tanni, E. S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101623
“These stronger effects likely reflect a greater reversal of the pathogenic factors in MASLD, such as obesity-driven insulin resistance and hyperinsulinemia [68,69].”
Rôle de FAT10 dans la sénescence des hépatocytes et le développement de la NASH
Bernard, L. (2023) · theses.fr (ABES) · doi:10.70675/793b0b93z9794z42d4zb8dfz5f3d68268a9b
Chang, D., McTigue, D. M., & Bruno, R. S. (2026) · Nutrition Research · doi:10.1016/j.nutres.2026.04.003
Watabe, H., Miyagaki, T., Go, K., Oba, S., 千晴, 野., & Kadono, T. (2026) · The Journal of Dermatology · doi:10.1111/1346-8138.70274
“Chronic hyperglycemia and insulin resistance have been reported to promote hepatic de novo lipogenesis, oxidative stress, and mitochondrial dysfunction, all of which may contribute to hepatocellular injury and fibrogenesis [10, 11].”
Ruan, S., Liu, S., Zhang, X., Zhang, J. Y., Chen, C., Lu, H., Zheng, K., Fang, S., & Chen, X. (2026) · Medicine · doi:10.1097/md.0000000000048269
“[13,58] The net effect is increased lipogenesis, reduced β -oxidation, and accumulation of TGs within hepatocytes, establishing the foundation of MASLD.”
Zhao, A. Y., Sun, H., Yan, L., Shiyanbola, O. O., Bridges, D., & Gregg, B. E. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70468 · Cited by 1
“Increased circulating insulin and glucose also stimulate hepatic de novo lipogenesis, contributing to hepatic steatosis [ 35 ].”
Metabolic features in plasma and urine of obese children and their association with MAFLD risk
Hu, S., Yan, W. S., Wu, S., Liu, Q., & Li, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1701999
“Under this condition, increased hepatic uptake of palmitic acid for de novo lipogenesis may result in decreased circulating levels, reflecting a consumption-driven rather than deficiency-driven phenomenon (29).”
Lee, J.-Y., Lee, J., Jung, W., Je, J., & Lee, S. G. (2026) · Cytotechnology · doi:10.1007/s10616-026-00967-z
“Hepatic de novo lipogenesis is a major driver of steatosis, particularly under conditions of insulin resistance and nutrient excess (Smith et al. 2020).”
Ethnic-specific ZJU index thresholds for hepatic steatosis and fibrosis in Chinese MASLD
Qiu, Y., Zhang, Z. J., Wan, Y., Zhang, Y., Hu, C., & Huang, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1799299
“Third, East Asians exhibit disproportionate insulin resistance compared to their BMI (25, 33), which drives increased hepatic de novo lipogenesis (DNL), the primary source of liver triglycerides in MASLD (35, 36).”
InfluentialWu, C., Lin, M., Wang, C.-Y., Chang, C.-Y., Lee, F., Cheng, M., Lin, Y., Chen, T., Hsiao, Y.-T., Wang, B.-W., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104186
“Disrupted serine or glycine metabolism often accompanies abnormal glucose homeostasis in selective insulin resistance that contributes to obesity-related MASLD [8,47].”
Liu, R., Ge, H., Qiu, C., & Wu, Z. (2026) · Journal of Clinical Hypertension · doi:10.1111/jch.70261
Endoplasmic Reticulum Associated Lipolysis Regulates Hepatic Fat Synthesis and TurnoverPreprint
Lian, J., Watts, R., Nelson, R., Kennelly, J. P., Thiesen, A., Quiroga, A. D., Vine, D. F., Clugston, R. D., Jacobs, R. L., & Lehner, R. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.08.723884
Kim, M., Ko, S., Kim, S., & Shin, D. (2026) · BMC Nutrition · doi:10.1186/s40795-026-01357-6
“…and carbohydrate-responsive element–binding protein — potentially stimulating de novo lipogenesis and VLDL-TG secretion, consistent with established mechanistic models, although direct measurement of amylase activity, insulin dynamics, and DNL markers was not performed in this cohort [46, 57, 58].”
Zhang, K., 吕梦蝶, Yang, Y., Huang, J., Li, L., Yan, Y., Li, R., & Yang, J. Q. (2026) · Phytotherapy Research · doi:10.1002/ptr.70287
“Numerous researchers have shown that insulin resistance brought on by malnutrition affects the accumulation and excretion of hepatic fatty acids, raising he-patic TG levels (Smith et al. 2020).”
Li, T., & Pan, S. (2026) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2026.175011
Hepatic amino acid metabolism in liver, cardiovascular, kidney and metabolic diseases
Flam, E. L., Tailleux, A., Haas, J. T., & Staels, B. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120756
Rong, L., Fan, H.-D., Fang, Q., Li, X., Tan, J., & Huang, J. (2026) · Medicine · doi:10.1097/md.0000000000049157
“[43,44] However, in diabetic patients, insulin resistance, hyperinsulinemia, and hyperglycemia can lead to elevated RC levels.”
Belanger, N., Zeid, S., Gieswinkel, A., Kazemi-Asrar, F., Velmeden, D., Rausch, F., Dinh, W., Lackner, K. J., Gori, T., Lurz, P. C., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag139
H2S-mediated protein S-sulfhydration: a novel regulatory module in lipid metabolism
Pang, M., Chen, H., Li, S., Yang, H., Mao, Y., & Huang, Y. Q. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1866744 · Cited by 1
“Chronic upregulation of DNL is associated with cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), and type 2 diabetes (Lai et al., 2019; Lawitz et al., 2018; Smith et al., 2020; Imamura et al., 2020).”
Cui, X., Xu, J., Wang, J., Xia, L., Fan, Y., Wang, L., Guo, S., Wang, D., Li, Q., Wu, S., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1824255
“Prior work has emphasized the adipocentric nature of steatotic liver disease, where increased lipid flux from adipose tissue, enhanced hepatic de novo lipogenesis, and impaired lipid export collectively drive intrahepatic triglyceride accumulation (26, 27).”
Xie, J., Zhang, J., Wang, Y., Chen, S., Zhu, Y., & Yin, D. (2026) · Journal of Food Quality · doi:10.1155/jfq/9705067
Cross, E., Westcott, F., Smith, K. H., Nagarajan, S. R., Sanna, F., Dennis, K. M. J. H., & Hodson, L. (2026) · Physiological Reports · doi:10.14814/phy2.70989
Kirichenko, T. V., Tolkachev, Y. D., Bessonov, S. M., Markin, A. M., & Markina, Y. V. (2026) · Biomedicines · doi:10.3390/biomedicines14071521
“According to studies, the contribution of de novo lipogenesis to palmitate synthesis leads to a 3-fold increase in NAFLD [41].”
Simmer, L. M., Nunes, F. M., Santos, K. V. D., Saiz, D. A. G., Miranda, K. O., Cordeiro, E. R., Boeloni, J. N., Bocalini, D. S., Leopoldo, A. S., & Lima‐Leopoldo, A. P. (2026) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2026e15127
“Obesity can lead to in fl ammation by impairing insulin signaling, which is re fl ected in the activation of intermediate in fl ammatory pathways through pro-in fl ammatory cytokines (38).”
Vajdi, M., Nikrad, N., Khajeh, M., Noshadi, N., Maroofi, M., Darzi, M., Tabrizi, F. P. F., & Askari, G. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02225-w
“Evidence show that insulin resistance and obesity contribute to increased inflammation [11, 12], on the other hand IR may increase de novo hepatic lipogenesis, exacerbating the fat accumulation in the liver [13].”
Glycerol 3-phosphate activates lipid metabolism through GATOR2-dependent regulation of mTORC1
Kwon, H., Yamada, S., Meng, L., Kwon, M., Xu, H., Chi, J., Radovick, S., Gu, H., He, L., & Wondisford, F. E. (2026) · Science Signaling · doi:10.1126/scisignal.aeb7989
Chen, F., Guan, Y., Liu, N., & Jing, W. (2026) · Comprehensive physiology · doi:10.1002/cph4.70218
Fainanta, T., Krusong, K., Saradhuldhat, W., Jatuyosporn, T., Tananuwong, K., & Jaroenporn, S. (2026) · Discover Food · doi:10.1007/s44187-026-01171-w
“Epidemiological and clinical evidence suggest that long-term exposure to high dietary glycemic load is associated with increased risk of T2DM and adverse cardio-metabolic outcomes, although this relationship depends on the overall dietary pattern and metabolic context [8, 9].”
Xuan, Y., Yu, J., & Yao, Q. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1868410
Lenz, B. Q., Ankley, G. T., & Etterson, M. A. (2026) · Environmental Toxicology and Chemistry · doi:10.1093/etojnl/vgag203
Wang, S., Gao, Y., Wang, Y., Wang, J., & Liu, Y. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1865475
“Although DNL is a normal metabolic pathway required for maintaining physiological homeostasis, abnormally increased DNL activity may lead to hepatic steatosis (Smith et al., 2020).”
Gupta, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44591-0.00003-5
Zhu, S., Yang, F., Lu, H., Jiang, J., & He, W. Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1843719
“The accumulation of intrahepatic steatosis is associated with the buildup of intrahepatic ceramides and diacylglycerols, which have been shown to inhibit insulin signaling, thereby leading to hepatic insulin resistance (84).”
Abady, E. M. A., AbuEl-Enien, H., Karam, K. N., Shahab, S. H., Fakhiraldeen, S., Kotak, P., Samadi, Y., & Yasin, Z. (2026) · Discover Medicine · doi:10.1007/s44337-026-00653-1 · Cited by 1
“These FFAs are delivered to the liver through the portal vein, overwhelming hepatic lipid handling capacity [32, 33].”
Zhang, Q., Hu, X.-D., Wang, Y.-M., Wang, X., Cao, X., Pan, L., Wang, Y.-M., Cao, L., & Shi, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04955-z
“Therefore, the present analysis is limited to basic glycemic markers (FBG and HbA1c) and cannot provide a direct evaluation of insulin resistance [24,25].”
Review on the Relationship Between TyG Index and CVD Incidence in Patients With T2DM With NAFLD
Zhu, Y., Yu, B., Huang, H., & Zhong, Z. (2026) · International Journal of Endocrinology · doi:10.1155/ije/6707256
“As shown in Figure 1, IR is undeniably a critical pathogenic factor and core pathological component in the development of T2DM with NAFLD [2, 3].”
MASLD: Spatial Mechanisms and New Therapeutics
Stoess, C., Onyuru, J., Hu, Y., Jiang, Y., Xin, Z., Panchal, A., & Hartmann, P. (2026) · Biomolecules · doi:10.3390/biom16081129
“…gluconeogenesis, whereas hyperinsulinemia and hyperglycemia continue to activate sterol regulatory element-binding protein 1c (SREBP-1c)- and carbohydrate-responsive element-binding protein (ChREBP)-dependent lipogenesis, sustaining de novo lipogenesis (DNL) and hepatic lipid deposition [35,40].”
Rocca, F. L., Privitera, G., Geraci, C., Morello, V., Geraci, G., Paternò, V., Santoro, C., & Esposito, R. (2026) · Nutrients · doi:10.3390/nu18152527
“…impaired postprandial anti-lipolytic action of insulin increases free fatty acid (FFA) delivery to the liver, where, once β -oxidation and VLDL secretion are exceeded, FFAs are re-esterified into triglycerides, while hyperinsulinaemia and glucose excess further stimulate de novo lipogenesis [73].”
Li, S., Zeng, Q., Liu, Y., Li, Y., Wang, N., Zheng, R., Zuo, B., Zhou, Y., & 蒋思文 (2026) · The FASEB Journal · doi:10.1096/fj.202600780rr
Kelley, E. E., Woodward, O. M., & Khoo, N. K. H. (2026) · Seminars in Liver Disease · doi:10.1055/a-2926-5268
Gao, L., Guo, Y., Cong, X., Yang, T., Ma, H., Wu, T., Ge, Z., Zhang, P., & Bi, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71238
Chan, A. P., Lai, R. W., & Calkins, K. L. (2026) · Nutrients · doi:10.3390/nu18172800
“At the same time, persistent insulin signaling promotes a lipogenic hepatic milieu, in which excess dextrose is converted to fat through de novo lipogenesis, contributing to hepatic steatosis and inflammation [50].”
Kumar, S., Aceves, M., Guerra, L., Granados, J., Novilla, E., Juarez, F., Oluwadairo, T., Leandro, A. C., Leandro, M., Peralta, J. M., et al. (2026) · Cells · doi:10.3390/cells15171592
Molecular smugglers in obesity-driven MASLD: Snitching on adipose-derived extracellular vesicles
Chen, Q., Shevchenko, T., Zhan, D., Ma, N., Lefere, S., Boeckmans, J., Kock, J. D., Goethem, F. V., He, Y., Vanhaecke, T., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.025
Molekulare Mechanismen der MASLD- und MASH-Entwicklung
Püschel, G. P. (2026) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2892-0948
“…und gleichzeitig durch die Hyperinsulinämie und das erhöhte Glukoseangebot die hepatische Fettsäuresynthese gesteigert wird, so dass man sagen kann, dass zumindest in späteren Stadien der Erkrankung die fort schreitende Steatose eher eine Folge der Insulinresistenz ist als ihre Ursache [33].”
Foia, L. G., Goriuc, A., Luchian, I. A., Budală, D. G., Toma, V., Bogdán, M., Minea, B., & Ghemiș, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177917
Khanuja, P. K., Mohan, V., Martinez, A. P., Nellutla, M., Alamgir, M., Anjum, A., Ahmad, F. A. J., Oguntona, T. S., Saari, H. A. M. A., Suresh, D., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1860047
“Major sources of hepatic fatty acids include nonesterified fatty acids released from adipose tissue, dietary fatty acids delivered through chylomicron remnants, and hepatic de novo lipogenesis from carbohydrate substrates (5, 17–19).”
Heerkens, L., van Duijnhoven, F. J. B., Pertiwi, K., & Geleijnse, J. M. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104997
Nayak, S. P. R. R., Devadoss, T., Chitra, V., Almutairi, B. O., Almutairi, M. H., Balasubramanian, B., Arasu, M. V., Kumaradoss, K. M., Palaniappan, S., Namasivayam, S. K. R., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118451
Zhu, X., Hu, X., Zhan, Z., Zeng, Z., Zhao, X., Li, H., Song, C., Li, B., & Jin, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933356
Qadir, A. M., & Omer, R. A. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00764-x
“…signalling Hepatic insulin resistance and de novo lipogenesis Hyperglycemia-driven fat synthesis Metabolic signalling modulators down-stream of THR [95] Oxidative stress and inflammation Hepatocellular injury Antioxidants; anti-inflammatory agents [96] Abbreviations : THR Thyroid hormone receptor,…”
Context-Dependent Roles of Liver Macrophages in MASH
Horn, P., & Tacke, F. (2026) · Seminars in Liver Disease · doi:10.1055/a-2954-5433
Mermutluoğlu, Ç., Taşova, Y., Mete, A. Ö., Karaoğlan, İ., Pullukçu, H., Sönmezer, M. Ç., İnan, D., Şimşek, F., Akhan, S., Çakırca, T. D., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198672
“Experimental and clinical studies have shown that reduced hepatic and systemic insulin sensitivity is associated with increased de novo lipogenesis and intrahepatic triglyceride accumulation [42].”
Phosarith, N., Siriwoharn, T., & Jirarattanarangsri, W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198631
“Enhancing insulin sensitivity reduces this process [44,45].”
MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management
Krzewiński, H., Wątroba, O., & Koza, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197540
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Moradi, S., Binoy, A., & Zhu, S. (2026) · Journal of Orthopaedic Research® · doi:10.1002/jor.70290
“Dysregulated DNL has been implicated in a wide range of pathological conditions, including cancer [29], cardiometabolic disease [30], and metabolic syndrome [31, 32].”
Zhang, Q., Chen, Y., Wang, D., Pereira, S., & Kurtyk, M. J. B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1951400
“Smith et al. further demonstrated in humans with obesity-associated nonalcoholic fatty liver disease that hepatic de novo lipogenesis was inversely associated with hepatic insulin sensitivity (80).”
Yu, F., Yin, S., Jiayu, Z., & Sun, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1969017
“Studies have demonstrated that even mild elevations in intrahepatic triglyceride (IHTG) content can induce this post-receptor resistance, with the severity of resistance positively correlated with the degree of hepatic steatosis (32, 33).”
Хавкин, А. И., Газаль, А., Михайлович, Н. К., Vasileva, K. A., Shrainer, E., Гурова, М. М., & Новикова, В. П. (2026) · Children s medicine of the North-West · doi:10.56871/cmn-w.2026.48.70.009
Mechanisms of Hepatic Insulin Resistance and Its Contribution to the Pathogenesis of Type 2 Diabetes
Onyango, A. N. (2026) · Comprehensive physiology · doi:10.1002/cph4.70285
Wei, X., Lin, L., Wang, X., Du, H., Zhang, M., Tang, K., Gao, H., Xie, X., Gao, J., Wang, X., et al. (2026) · Advanced Science · doi:10.1002/advs.78372
“The accumulation of lipotoxic intermediates disrupts mitochondrial function and enhances oxidative stress, leading to excessive production of reactive oxygen species that impair cellular organelles and activate endoplasmic reticulum stress pathways [ 9, 10 ].”
Wei, J., Wang, N., Wang, Q., Liu, J., Cai, M., Zhang, L., Han, Y., Guo, J., & Zhong, S. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/6824542
Metabolic heterogeneity of obesity
Smith, G. I., Petersen, M. C., Hartig, S. M., & Klein, S. (2026) · Nature Medicine · doi:10.1038/s41591-026-04718-7
Self-citation
Metadata
- Authors
- Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., Sirlin, C. B., Talukdar, S., Hellerstein, M. K., & Klein, S.
- Affiliations
- Washington University in St. Louis (US)
- University of California, Berkeley (US)
- University of California San Diego (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Klein, Samuel
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1453-1460
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269561
- OpenAlex
- W2993862932
- Cited by
- 771
- References
- 65
- Citations by year
- 2026: 121 · 2025: 136 · 2024: 153 · 2023: 123 · 2022: 104 · 2021: 92 · 2020: 40
- FWCI
- 44.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (DK56341,DK20579,DK52574,RR024992)
- College of Natural Resources, University of California at Berkeley (N/A)
- Pershing Square Foundation (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, hepatic de novo lipogenesis, insulin resistance, intrahepatic triglyceride, hepatic insulin sensitivity, weight loss, obesity, hepatic steatosis, plasma glucose, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Insulin, Insulin Resistance, Liver, Male, Triglycerides, Palmitic Acid, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.